Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-8: Lonsurf + panitumumab vs Lonsurf + bevacizumab in first-line metastatic colorectal cancer
2024-513723-16-00Phase 2Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic colon cancer (mCRC) comparing Lonsurf + panitumumab with Lonsurf + bevacizumab (2 arms). Primary endpoint: Objective response rate (ORR) per RECIST 1.1 (local assessment). Planned start Oct 2024; status: authorised.
02
Drugs
trifluridine + tipiracilpanitumumabbevacizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2024-513723-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513723-16-00.